Zota Health Care Ltd
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.[1]
- Market Cap ₹ 4,170 Cr.
- Current Price ₹ 1,204
- High / Low ₹ 1,740 / 917
- Stock P/E 146
- Book Value ₹ 256
- Dividend Yield 0.08 %
- ROCE 6.68 %
- ROE 4.74 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 94.7% CAGR over last 5 years
Cons
- Stock is trading at 4.70 times its book value
- Promoter holding has decreased over last quarter: -1.25%
- Company has a low return on equity of 4.36% over last 3 years.
- Earnings include an other income of Rs.12.4 Cr.
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56 | 64 | 70 | 77 | 85 | 95 | 106 | 131 | 138 | 166 | 256 | 407 | |
| 47 | 55 | 60 | 66 | 77 | 90 | 105 | 116 | 130 | 160 | 245 | 375 | |
| Operating Profit | 8 | 10 | 10 | 11 | 8 | 5 | 1 | 15 | 8 | 6 | 11 | 32 |
| OPM % | 15% | 15% | 14% | 14% | 9% | 5% | 1% | 12% | 6% | 4% | 4% | 8% |
| 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 5 | 12 | |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Depreciation | 2 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 | 3 | 4 |
| Profit before tax | 6 | 8 | 8 | 11 | 8 | 4 | -0 | 14 | 9 | 5 | 12 | 40 |
| Tax % | 33% | 34% | 34% | 36% | 29% | 29% | -47% | 25% | 24% | 31% | 27% | 30% |
| 4 | 5 | 6 | 7 | 6 | 3 | -0 | 11 | 7 | 3 | 9 | 28 | |
| EPS in Rs | 2.12 | 2.54 | 2.76 | 2.96 | 2.26 | 1.12 | -0.07 | 4.21 | 2.62 | 1.31 | 3.01 | 8.06 |
| Dividend Payout % | 34% | 28% | 52% | 72% | 32% | 89% | -1,535% | 36% | 38% | 76% | 33% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 31% |
| 3 Years: | 44% |
| TTM: | 59% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 95% |
| 3 Years: | 67% |
| TTM: | 232% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 58% |
| 1 Year: | 28% |
| Return on Equity | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 5% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 14 | 14 | 14 | 18 | 18 | 25 | 25 | 25 | 25 | 26 | 29 | 35 |
| Reserves | 4 | 7 | 13 | 52 | 51 | 44 | 42 | 66 | 69 | 96 | 289 | 854 |
| 5 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 0 | 22 | |
| 15 | 20 | 23 | 22 | 21 | 20 | 19 | 34 | 30 | 37 | 62 | 106 | |
| Total Liabilities | 38 | 44 | 54 | 92 | 90 | 88 | 86 | 125 | 125 | 173 | 380 | 1,016 |
| 8 | 7 | 7 | 10 | 10 | 15 | 14 | 13 | 11 | 12 | 12 | 582 | |
| CWIP | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 3 | 5 | 6 | 0 |
| Investments | 0 | 0 | 0 | 26 | 16 | 14 | 10 | 35 | 10 | 7 | 116 | 0 |
| 30 | 36 | 45 | 56 | 63 | 59 | 62 | 78 | 101 | 150 | 246 | 434 | |
| Total Assets | 38 | 44 | 54 | 92 | 90 | 88 | 86 | 125 | 125 | 173 | 380 | 1,016 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | 5 | 3 | -4 | -3 | 6 | -1 | 14 | -10 | -30 | -22 | -46 | |
| -1 | -1 | -2 | -26 | 9 | -4 | 4 | -27 | 13 | -9 | -148 | -515 | |
| -4 | -3 | -2 | 33 | -6 | -3 | -2 | 14 | -4 | 38 | 171 | 561 | |
| Net Cash Flow | 0 | 1 | -1 | 2 | -1 | -1 | 1 | 1 | -1 | -1 | 1 | 0 |
| Free Cash Flow | 4 | 3 | 1 | -6 | -6 | -1 | -2 | 12 | -14 | -35 | -26 | -66 |
| CFO/OP | 76% | 76% | 62% | -4% | -12% | 146% | -116% | 113% | -102% | -460% | -164% | -110% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 77 | 90 | 88 | 109 | 95 | 112 | 99 | 107 | 115 | 162 | 147 | 157 |
| Inventory Days | 175 | 141 | 193 | 174 | 207 | 139 | 139 | 116 | 148 | 139 | 138 | 133 |
| Days Payable | 116 | 126 | 148 | 118 | 103 | 82 | 77 | 76 | 102 | 107 | 107 | 122 |
| Cash Conversion Cycle | 135 | 105 | 133 | 165 | 199 | 169 | 161 | 147 | 161 | 194 | 178 | 168 |
| Working Capital Days | 67 | 85 | 106 | 151 | 175 | 152 | 143 | 112 | 153 | 172 | 177 | 155 |
| ROCE % | 32% | 36% | 33% | 23% | 11% | 6% | -2% | 18% | 9% | 5% | 6% | 7% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Davaindia Stores Number |
|
||||||||
| Domestic Marketing Distributors Number |
|||||||||
| Davaindia COCO Stores Number |
|||||||||
| Davaindia Portfolio SKUs Number |
|||||||||
| Export Dossiers Registered Number |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
5 June 2026 - Zota Health Care will attend Nirmal Bang Securities Investor Conference on June 15, 2026.
-
Disclosure under SEBI Takeover Regulations
5 June 2026 - HIMANSHU Muktilal ZOTA has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the SEBI (Substantial Acquisition of Shares …
-
Analysts/Institutional Investor Meet/Con. Call Updates
29 May 2026 - Zota Health Care released Q4/FY26 earnings call transcript; FY26 revenue rose 83.86% to INR 538.65 crore, EBITDA positive.
-
Analysts/Institutional Investor Meet/Con. Call Updates
26 May 2026 - Zota Health Care to attend Axis Capital’s Rising Stars Conference on June 2, 2026 in Mumbai.
-
Analysts/Institutional Investor Meet/Con. Call Updates
25 May 2026 - Audio recording link shared for FY26 Q4 and annual earnings conference call.
Annual reports
Concalls
-
May 2026TranscriptPPT
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Oct 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT
-
Jul 2025TranscriptAI SummaryPPT
-
Jun 2025Transcript PPT
-
Apr 2025TranscriptAI SummaryPPT
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jun 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
Sep 2022TranscriptAI SummaryPPT
-
Jun 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Dec 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
Jun 2021TranscriptAI SummaryPPT
-
Feb 2021TranscriptAI SummaryPPT
-
Dec 2020TranscriptAI SummaryPPT
-
Sep 2020TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
Business segments & Revenue 9MFY26[1][2]
A. Domestic sales (13%):[3] The company’s domestic marketing business(oldest vertical) is supported by a distribution network of 1,050+ distributors and a portfolio of 4,000+ products across multiple therapeutic segments. It sources formulations from domestic manufacturers, including those recognised by global health agencies, and distributes them across the country.